ADC Therapeutics SA (ADCT) vs Oramed Pharmaceuticals (ORMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Oramed Pharmaceuticals (ORMP) has outperformed ADC Therapeutics SA (ADCT) over the past year, gaining 76.2% versus a loss of 67.1%. Over five years, ORMP leads with a -80.2% price change compared with -94.4% for ADCT. ADC Therapeutics SA is the larger company by market cap ($194.7 million vs $175.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | ORMP |
|---|---|---|
| Share price | $1.53 | $4.21 |
| Market cap | $194.69M | $175.12M |
| 1-day change | +7.39% | -3.66% |
| YTD return | -59.77% | +53.33% |
| 1-year return | -67.05% | +76.21% |
| 5-year return | -94.42% | -80.19% |
| P/E ratio (TTM) | — | 1.02 |
| EPS (TTM) | $-0.60 | $4.13 |
| Dividend yield | 0.00% | 5.71% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $5.47 |
| 52-week low | $0.78 | $2.09 |
| Distance from 52-week high | -69.38% | -23.03% |
| Analyst consensus | none | none |
| Avg. price target upside | +118.36% | +66.27% |
| Average volume | 1.35M | 192.76K |
| Shares outstanding | 127.67M | 41.60M |
| Employees | 188 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORMP has outperformed ADCT by 143.3 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (5.71% vs 0.00%).
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
ADCT vs ORMP FAQ
Which is bigger, ADC Therapeutics SA or Oramed Pharmaceuticals?
ADC Therapeutics SA (ADCT) is larger, with a market capitalization of $194.69M compared with $175.12M for Oramed Pharmaceuticals (ORMP).
Which stock has performed better over the past year, ADCT or ORMP?
ORMP returned +76.21% over the past 12 months, compared with -67.05% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, ADC Therapeutics SA or Oramed Pharmaceuticals?
Oramed Pharmaceuticals pays a dividend yielding 5.71%, while ADC Therapeutics SA does not currently pay a regular dividend.
Are ADC Therapeutics SA and Oramed Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.